Nyctea Technologies - A new protein separation for the next generation of pharmaceuticals
| Reference number | |
| Coordinator | Nyctea Technologies AB |
| Funding from Vinnova | SEK 299 409 |
| Project duration | May 2021 - October 2021 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups step 1 spring 2021 |
Important results from the project
The aim project was to develop a prototype for a more efficient purification of protein pharmaceuticals and to create an interest for this technology among potential customers in the pharmaceutical industry. We succeeded in creating a functional prototype which purifies proteins on a meaningful scale using a new unique mechanism for separation. We successfully tested our prototype with potential customers in their lab and on their commercial systems for protein purification.
Expected long term effects
The result obtained is a prototype, ready to be tested by customers. This was used to spread knowledge about our new technology for protein purification among globally and locally active key players in the industry. Our expectation is now to take the next step in the company´s development, to launch a product based on our technology and initiate sales to customers that we have already engaged in conversations and experimental tests. The effect is that we can quickly develop the product to become a strong and marketable alternative.
Approach and implementation
We had a clear hypothesis for how the technical challenges we faced with building the prototype could be solved. We managed to build a functional prototype early in the project which lead to a faster evaluation together with the customer enabled us to perform re-iterations of the design already within the timeframe of the project. We had a basic understanding of the market demand prior to the start of the project and good contacts in industry and academia which guided us from the start to finish with fast and relevant feedback.